No Detail Found!

The sofosbuvir plus ribavirin vs sofosbuvir plus daclatasvir in obtaining sustained viral response in chronic hepatitis c.

Author(s)
Malik Muhammad Waseem Services Hospital, Lahore, Pakistan
Irfan Younus Nawaz Sharif Medical College, Gujrat, Pakistan
Muhammad Habib Mayo Hospital, Lahore, Pakistan
Adnan Qadir Islamic International Medical College, Rawalpindi, Pakistan
Shahid Sarwar SIMS, Lahore, Pakistan
Zameer Butt Aziz Bhatti Shaheed Teaching Hospital, Gujrat, Pakistan
Abstract
Objective: To compare the Sustained viral response (SVR) in patients who had taken Sofosbuvir plus Ribavirin for 24 weeks and Sofosbuvir plus Daclatasvir for 12 weeks to treat hepatitis C. Study Design: Randomized Control Trial. Setting: Medical Division of Mayo Hospital, Lahore. Period: One Year duration, 2021. Material & Methods: 130 patients of chronic Hepatitis C were divided into two categories based on whether they met the inclusion requirements. In Group A patients used sofosbuvir plus ribavirin for six months, whereas patients of Group B took sofosbuvir plus daclatasvir for 3 months. In order to determine SVR, PCR for HCV RNA Quantitative was done at week twelve after completion of the course. SPSS 23.0 was applied to enter and analyze the data. Results: All cases had an average age of 48.80 + 16.63 years, whereas it was 48.09 +16.43 years for group A and 49.51+ 16.92 years for groups B. In group A, there were 39 cases (60%) of men and 26 cases (40%) of women, while in group B, there were 34 instances (52.3% men and 31 cases (47.7% women). SVR was attained in 34 (52.34%) of group A participants and 54 (83.12%) of group B participants (p-value of 0.001). Conclusion: Sof+Dacla group had significantly high SVR than Sof+Riba group especially in non-cirrhotic and treatment-naïve individuals.
Publication Details
Page(s) 1574-1577
DOI 10.29309/TPMJ/2023.30.12.7608
Published Journal: Professional Medical Journal, Volume: 30, Issue: 12, Year: 2023

Request the full text from PASTIC

Keywords
PCR, HCV, ribavirin, Daclatasvir, Sofosbuvir., Sustained viral response
More from Professional Medical Journal
0

Citations

0

Downloads

31

Views

Copyright ©  PASTIC National Center, Islamabad www.pastic.gov.pk